TY - JOUR
T1 - 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA)
T2 - An open-label, randomised controlled trial
AU - Goldhirsch, Aron
AU - Gelber, Richard D.
AU - Piccart-Gebhart, Martine J.
AU - De Azambuja, Evandro
AU - Procter, Marion
AU - Suter, Thomas M.
AU - Jackisch, Christian
AU - Cameron, David
AU - Weber, Harald A.
AU - Heinzmann, Dominik
AU - Lago, Lissandra Dal
AU - McFadden, Eleanor
AU - Dowsett, Mitch
AU - Untch, Michael
AU - Gianni, Luca
AU - Bell, Richard
AU - Köhne, Claus Henning
AU - Vindevoghel, Anita
AU - Andersson, Michael
AU - Brunt, A. Murray
AU - Otero-Reyes, Douglas
AU - Song, Santai
AU - Smith, Ian
AU - Leyland-Jones, Brian
AU - Baselga, Jose
PY - 2013
Y1 - 2013
N2 - Background Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial. Methods The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant chemotherapy, adjuvant chemotherapy, or both in 5102 patients with HER2-positive early breast cancer. The primary endpoint was disease-free survival. The comparison of 2 years versus 1 year of trastuzumab treatment involved a landmark analysis of 3105 patients who were disease-free 12 months after randomisation to one of the trastuzumab groups, and was planned after observing at least 725 disease-free survival events. The updated intention-to-treat comparison of 1 year trastuzumab treatment versus observation alone in 3399 patients at a median follow-up of 8 years (range 0-10) is also reported. This study is registered with ClinicalTrials.gov, number NCT00045032. Findings We recorded 367 events of disease-free survival in 1552 patients in the 1 year group and 367 events in 1553 patients in the 2 year group (hazard ratio [HR] 0·99, 95% CI 0·85-1·14, p=0·86). Grade 3-4 adverse events and decreases in left ventricular ejection fraction during treatment were reported more frequently in the 2 year treatment group than in the 1 year group (342 [20·4%] vs 275 [16·3%] grade 3-4 adverse events, and 120 [7·2%] vs 69 [4·1%] decreases in left ventricular ejection fraction, respectively). HRs for a comparison of 1 year of trastuzumab treatment versus observation were 0·76 (95% CI 0·67-0·86, p
AB - Background Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial. Methods The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant chemotherapy, adjuvant chemotherapy, or both in 5102 patients with HER2-positive early breast cancer. The primary endpoint was disease-free survival. The comparison of 2 years versus 1 year of trastuzumab treatment involved a landmark analysis of 3105 patients who were disease-free 12 months after randomisation to one of the trastuzumab groups, and was planned after observing at least 725 disease-free survival events. The updated intention-to-treat comparison of 1 year trastuzumab treatment versus observation alone in 3399 patients at a median follow-up of 8 years (range 0-10) is also reported. This study is registered with ClinicalTrials.gov, number NCT00045032. Findings We recorded 367 events of disease-free survival in 1552 patients in the 1 year group and 367 events in 1553 patients in the 2 year group (hazard ratio [HR] 0·99, 95% CI 0·85-1·14, p=0·86). Grade 3-4 adverse events and decreases in left ventricular ejection fraction during treatment were reported more frequently in the 2 year treatment group than in the 1 year group (342 [20·4%] vs 275 [16·3%] grade 3-4 adverse events, and 120 [7·2%] vs 69 [4·1%] decreases in left ventricular ejection fraction, respectively). HRs for a comparison of 1 year of trastuzumab treatment versus observation were 0·76 (95% CI 0·67-0·86, p
UR - http://www.scopus.com/inward/record.url?scp=84884418164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884418164&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(13)61094-6
DO - 10.1016/S0140-6736(13)61094-6
M3 - Article
C2 - 23871490
AN - SCOPUS:84884418164
VL - 382
SP - 1021
EP - 1028
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9897
ER -